Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2482195 | 0.98 | DYRK1A (0.58) | DYRK1AFLT3CA2NPC1MAOB | |
| Dimethylamine SCHEMBL2103953 | 0.94 | DYRK1A (0.54) | DYRK1AFLT3CA2NPC1MAOB | |
| Oxalic Acid SCHEMBL6591344 | 0.89 | FLT3 (0.59) | DYRK1AFLT3CA2NPC1MAOB | |
| SCHEMBL6980491 | 0.83 | CA2 (0.52) | DYRK1AFLT3CA2NPC1RAB9A | |
| SCHEMBL3920685 | 0.77 | FLT3 (0.59) | FLT3CA2NPC1MAOBRAB9A | |
| SCHEMBL170369 | 0.77 | ALDH1A1 (0.55) | DYRK1ACA2MAOBALDH1A1APP | |
| SCHEMBL16284310 | 0.76 | NPC1 (0.57) | FLT3CA2NPC1MAOBRAB9A | |
| SCHEMBL22312245 | 0.75 | DYRK1A (0.51) | DYRK1ANPC1MAOBRAB9AKDM4E | |
| SCHEMBL1746909 | 0.74 | DYRK1A (0.50) | DYRK1ACA2MAOBMAPTSMN1; SMN2 | |
| SCHEMBL12778679 | 0.74 | FLT3 (0.55) | FLT3CA2NPC1MAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023102162-A1 | TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220098154-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3917627-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160134-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3144301-B1 | COMPOUND, ORGANIC OPTOELECTRONIC ELEMENT COMPRISING SAME AND DISPLAY DEVICE THEREOF | SAMSUNG SDI CO LTD (KR) | 2019-09-18 | — | — | EP | disclosed |
| EP-2836494-B1 | NEW ALKYLATING AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-08-21 | — | — | EP | disclosed |
| US-10266547-B2 | Thieno[2,3-e]indole derivatives as new antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-04-23 | — | — | US | disclosed |
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6511973-B2 | Enzyme inhibitors of blood coaggulation factor X for use as anticoaggulants in the treatment of cardiovascular diseases associated with thromboses | BRISTOL-MYERS SQUIBB CO. | 2003-01-28 | — | — | US | disclosed |
| US-20020045616-A1 | Lactam inhibitors of FXa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-18 | — | — | US | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2002010159-A1 | LACTAM INHIBITORS OF FACTOR XA WHICH ARE USEFUL FOR THE TREATMENT OF THROMBOSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1156803-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6297233-B1 | Lactam inhibitors of FXa and method | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |
| WO-2000047207-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098154-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLH, POLB | DYRK1A 4204/4885FLT3 1217/4885CA2 2547/4885 |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | DYRK1A 3751/4885FLT3 3831/4885CA2 2662/4885 |
| US-10266547-B2 | Thieno[2,3-e]indole derivatives as new antitumor agents | INMT, TOP2A, TOP1 | DYRK1A 829/4885FLT3 2161/4885CA2 3469/4885 |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | YEATS2, YEATS4, KNTC1 | DYRK1A 1827/4885FLT3 1990/4885CA2 3497/4885 |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | DYRK1A 4096/4885FLT3 802/4885CA2 3830/4885 |
| US-20020045616-A1 | Lactam inhibitors of FXa and method | F11, TFPI, F2 | DYRK1A 4084/4885FLT3 1889/4885CA2 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.